Nationwide Children's News Releases

Nationwide Children’s Hospital Announces Plans for Andelyn Biosciences
Jan 13, 2020

Nationwide Children’s Hospital Announces Plans for Andelyn Biosciences

Central Ohio’s first commercial-scale gene therapy Good Manufacturing Practices (cGMP) clinical manufacturing facility slated for 2023.

May 29, 2019

Nationwide Children’s Hospital Named a CMT Center of Excellence

The Charcot-Marie-Tooth Association has named Nationwide Children’s Hospital a CMT Center of Excellence, in recognition of the comprehensive care and expertise provided to children with the most common form of Charcot-Marie-Tooth disease, CMT1A.

FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
May 24, 2019

FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital

Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.

Nationwide Children’s Hospital Dedicates Abigail Wexner Research Institute at Nationwide Children’s Hospital
May 21, 2019

Nationwide Children’s Hospital Dedicates Abigail Wexner Research Institute at Nationwide Children’s Hospital

Nationwide Children’s Hospital dedicated the hospital’s Research Institute as the Abigail Wexner Research Institute at Nationwide Children’s Hospital. This naming recognizes Mrs. Wexner, whose ongoing, passionate advocacy has ushered in a period of unprecedented transformation at the hospital.

May 20, 2019

MEDIA ADVISORY: Dedication of the Abigail Wexner Research Institute at Nationwide Children’s Hospital

WHAT: The dedication of the Abigail Wexner Research Institute at Nationwide Children’s Hospital and announcement of the Allen Distinguished Scholar in Pediatric Research WHEN: Tuesday, May 21, 2019 10:30 a.m. – Media Tour of the Abigail Wexner Research Institute 11:30 a.m.

Apr 01, 2019

Anne M. Connolly, MD, Named Division Chief of Neurology at Nationwide Children’s Hospital

Anne M. Connolly, MD, has joined Nationwide Children’s Hospital as division chief of Neurology and a member of the Center for Gene Therapy.

Nationwide Children’s Hospital  Announces Plans to Dedicate the Abigail Wexner Research Institute
Jan 25, 2019

Nationwide Children’s Hospital Announces Plans to Dedicate the Abigail Wexner Research Institute

Ms. Wexner’s partnership with her fellow board members, Chief Executive Officer Steve Allen, MD, and the Nationwide Children’s executive team made this evolution possible. In recognition of Dr. Allen’s role, Nationwide Children’s will also establish the Allen Distinguished Scholar in Pediatric Research.

Apr 24, 2018

Nationwide Children’s Researcher Wins Distinguished Clinical Research Achievement Award

The Clinical Research (CR) Forum, a non-profit membership association of top clinical research experts and thought leaders from the nation’s leading academic health centers, presented the Distinguished Clinical Research Achievement Award to two outstanding studies at the Top Ten Clinical Research Achievement Awards on April 18th at the National Press Club in Washington, D.C.

Nationwide Children's Hospital Study Named Among Top Ten Clinical Research Achievement Awards by the Clinical Research Forum
Mar 27, 2018

Nationwide Children's Hospital Study Named Among Top Ten Clinical Research Achievement Awards by the Clinical Research Forum

The first clinical trial to test the functional replacement of the mutated gene responsible for SMA1 will be recognized at the 2018 Top Ten Clinical Research Achievement Awards at the National Press Club in Washington, D.C., on April 18, 2018.

Phase 1 Study Shows Encouraging Data for Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Nov 01, 2017

Phase 1 Study Shows Encouraging Data for Gene Replacement Therapy for Spinal Muscular Atrophy Type 1

A one-time intravenous infusion of the high dose of gene therapy extended the survival of patients with spinal muscular atrophy type 1 (SMA1) in a Phase 1 clinical trial, according to a study published today in the New England Journal of Medicine. The study was conducted by Researchers from Nationwide Children’s Hospital in collaboration with AveXis, Inc. and The Ohio State University College of Medicine.